Lower Respiratory Tract Infection: 
An Unrecognised Risk Factor for High Altitude Pulmonary Oedema?

Christopher P Humphries
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

Received: 22/11/2016
Accepted: 16/12/2016
Published: 13/01/2017

How to cite this article: Humphries CP. Lower respiratory tract infection: an unrecognised risk factor for high altitude pulmonary oedema? EJCRIM 2017;4: doi:10.12890/2017_000539

Conflicts of Interests: The Authors declare that there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT
The case of a 25-year-old expedition doctor who developed high altitude pulmonary oedema (HAPE) while climbing in the Swiss Alps is presented, with reference to the literature. The patient’s symptoms of HAPE were typical. Less typical was the fact that the doctor had previously been to similar altitudes uneventfully. The only differentiator is that on this expedition he developed a mild lower respiratory tract infection (LRTI) 2 days prior to travel. There has been limited, conflicting evidence regarding LRTI as a risk factor for HAPE and high quality research has not focused on this area. LRTI is not commonly recognised as being a risk in high altitude environments, which may be resulting in lethal consequences. This report aims to inform, provide a clinical question for future high altitude research expeditions, and encourage consideration by expedition and high altitude doctors.

LEARNING POINTS
• Lower respiratory tract infection (LRTI) may be a significant risk factor in the development of high altitude pulmonary oedema (HAPE).
• The diagnosis of HAPE is clinical as investigations have been shown to be unreliable.
• The Lake Louise HAPE criteria provide a reasonable identification framework but may miss the early stages.

KEYWORDS
High altitude pulmonary oedema; oedema; infection; respiratory; risk

INTRODUCTION
High altitude pulmonary oedema (HAPE) is a non-cardiogenic pulmonary oedema. It is generally agreed that the cause is pulmonary vasoconstriction causing pulmonary hypertension[1–4]. Publications on infection as a risk in the development of altitude illnesses are few and conflicting[5,6]. Risk factors are predominantly identified as congenital or genetic[7], which is surprising as we know that lower respiratory tract infections (LRTIs) impair gas diffusion[8]. The author has been unable to discover any publications in which a subject has ascended to high altitude repeatedly with different effects.
The incidence of HAPE ranges from 0.2% to 15.0%[9]. However, the disease burden is poorly described and can be lethal or require dangerous rescues. Recognition of potential risk factors is therefore important.

CASE PRESENTATION
The patient planned to ascend Monte Rosa (elevation 4634 m) in the Swiss Alps. He had previously made several trips following itineraries...
with similar acclimatisation profiles (Table 1, Fig.1).

Two days previously, he developed a mild LRTI, producing some yellow sputum. He commenced acetazolamide as planned, as a prophylactic against acute mountain sickness. The cough settled on day 3, and he remained asymptomatic until day 5, when after 4 h (altitude 3500 m), he began experiencing subjectively decreased exercise tolerance. He was found to have normal respiratory and heart rates, and did not meet the Lake Louise HAPE criteria[10]. It was felt his experience represented a normal response to altitude. After 8 h (altitude 4200 m), the patient had dyspnoea at rest, cough, decreased exercise performance, and was tachycardic. A provisional diagnosis of HAPE was made and nifedipine commenced[11]. Descent would mean crossing a crevasse field at night, so a decision was made to continue on to a hut with communications and supplementary oxygen. At 17 h (altitude 4500 m), a rope became stuck so the patient bivouacked until morning. His respiratory rate reached 50–60 bpm, with significant orthopnoea (Fig. 2). Exercise tolerance was 10 yards. At 29 h, the patient was evacuated (to 673 m) providing significant symptomatic improvement.

| Day | Highest altitude reached | Altitude of sleep |
|-----|--------------------------|-------------------|
| 1   | 2500 m (approx, in plane cabin) | 673 m (Visp) |
| 2   | 3883 m (Klein Matterhorn) | 1608 m (Zermatt) |
| 3   | 4164 m (Breithorn) | 1608 m (Zermatt) |
| 4   | 3135 m (Gornergrat) | 2883 m (Monte Rosa hut) |
| 5   | 4634 m (Dufourspitze) | 4500 m (approx, Dufourspitze ridge) |
| 6   | 673 m (Visp) | 673 m (Visp) |
| 7   | 673 m (Visp) | 673 m (Visp) |
| 8   | 1608 m (return to Zermatt) | 1608 m (Zermatt) |

Table 1. Daily maximum altitude and altitude of sleep

Figure 1. Graph of ascent profile, sleep profile and partial pressure of oxygen against time

Figure 2. The patient (right) and climbing partner after a cold night at approximately 4500 m
INVESTIGATIONS

Arterial blood analysis demonstrated a metabolic acidosis (a recognised side effect of acetazolamide\(^{12}\), extracellular fluid depletion\(^{13}\) and ketogenesis\(^{14}\) and type 1 respiratory failure. Significant improvement was demonstrated at 24 h (Tables 2, 3).

Interestingly, the chest radiograph did not demonstrate pulmonary oedema (Figs. 3, 4). It has been established that radiograph results do not correlate with pulmonary artery wedge pressure (PAWP), and that relying on the absence of radiographic findings can lead to inaccurate diagnosis\(^{15}\). Evidence for HAPE elevating PAWP is conflicting\(^{16–18}\), but HAPE does produce extensive non-uniform pulmonary vasoconstriction\(^{19}\), which would likely cause similar effects.

| ABG test      | Day 6 | Day 7 |
|---------------|-------|-------|
| pH            | 7.30  | 7.43  |
| \(pO_2\) (mmHg) | 66   | 86    |
| \(pCO_2\) (mmHg) | 23   | 27    |
| BE (mmol/l)   | -14.0 | -6.0  |
| Bicarbonate (mmol/l) | 14.2 | 20.4  |
| Lactate (mmol/l) | 0.80 | 0.60  |
| \(FiO_2\)    | 21%   | 21%   |
| Temperature   | 36.9  | 36.6  |
| Aa gradient (mmHg, assumed respiratory quotient 0.8) | 41.6 | 16.8  |
| Expected Aa gradient (mmHg) | 7.2  | 7.8   |

Table 2. Arterial blood gas analysis at 673 m (abnormal results in bold).

| Peripheral venepuncture | Day 6 | Day 7 | Day 8 |
|-------------------------|-------|-------|-------|
| Leukocytes (+10^9/l)    | 23.9  | 8.7   | 6.1   |
| Neutrophil granulocytosis | Massive | -     | -     |
| Haemoglobin (g/l)       | 139   | 125   | 126   |
| Haematocrit             | 0.42  | 0.37  | 0.37  |
| C-reactive protein (mg/l) | -   | 66.7  | 21.0  |
| Procalcitonin (µg/l)    | -     | 0.60  |       |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | -  | >90   | >90   |
| Urinary ketones (mmol/l) | 15   | -     | -     |
| (1+)                    |       |       |       |

Table 3. Relevant haematology, biochemistry and urinalysis results (abnormal results in bold).
MEDIA

Differential Diagnosis
There are many causes of tachypnoea at altitude, but few cause such rapid onset and deterioration. There was no significant medical history, wheeze, smoking history, history of cardiac defect, radiographic findings, chest pain, anxiety, onset suggestive of pulmonary embolism, or findings consistent with deep vein thrombosis.
Key in the diagnosis of LRTI as a precipitating factor is that the patient had previous ascents to similar altitudes, following similar acclimatisation profiles.
The medical team made a diagnosis of:
1. HAPE
2. LRTI exacerbated by altitude.

Treatment
As with all cases of HAPE, the primary treatment was descent [20]. Treatment given consisted of salbutamol nebulisers (for subjective chest tightness and mucolysis), oral levofloxacin and fluid rehydration. Acetazolamide and nifedipine were discontinued due to improvement.

Outcome
Exercise tolerance improved to baseline over 14 days. The patient has since returned to similar altitudes without ill effect.

References
1. Zhou Q. Changes of pulmonary vasoactive factors and its relation with pulmonary arterial hypertension in patients with high altitude pulmonary edema. Cardiovasc Res 2014;103:557–594.
2. Luks AM. Physiology in medicine: a physiologic approach to prevention and treatment of acute high-altitude illnesses. J Appl Physiol 2015;118:509–519.
3. Shoene RB, Swenson ER. High-altitude pulmonary edema. In: Swenson ER, Bartsch P, editors. High altitude: human adaptation to hypoxia. New York: Springer; 2014, pp. 405–427.
4. Scherrer U, Rexhaj E, Jayet PY, Allemann Y, Sartori C. New insights in the pathogenesis of high-altitude pulmonary edema. Prog Cardiovasc Dis 2010;52:485–492.
5. Hacket PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976;308:1149–1155.
6. Murdoch DR. Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat Space Environ Med 1995;66:148–151.
7. West JB, Schoene RB, Luks AM, Milledge JS. In: West JB, Schoene RB, Luks AM, Milledge JS, editors. High altitude medicine and physiology. Boca Raton, FL: CRC Press; 2013, p. 315–316.
8. Shalbe B, Schaffer K, Taylor CT. Hypoxia, innate immunity and infection in the lung. Respir Physiol Neurobiol 2010;174:235–243.
9. Luks AM, Schoene ER. Travel to high altitude with pre-existing lung disease. Eur Respir J 2007;29:770–792.
10. The Lake Louise Consensus on the Definition and Quantification of Altitude Illness. In: Sutton JR, Coates G, Houston CS, editors. Hypoxia and mountain medicine. Burlington, VT: Queen City Printers; 1992.
11. Oelz O, Ritter M, Jenni R, et al. Nifedipine for high altitude pulmonary oedema. Lancet 1989;334:1241–1244.
12. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide. Not a rare complication. Arch Intern Med 1985;145:1815–1817.
13. Wrenn KD, Stols CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med 1991;91:119–128.
14. Fukao T, Mitchell G, Sass JO, Hori T, Orii K, Aoyama Y. Ketone body metabolism and its defects. J Inherit Metab Dis 2014;37:541–551.
15. Chakko S, Woská D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 1993;90:353–359.
16. Labrousse J, Tenailleau A, Massable P, Simonneau G, Lissac J. Effect of artificial ventilation on pulmonary capillary pressure in acute respiratory insufficiency. Nouv Presse Med 1977;6:1639–1642.
17. Maggiorini M, Melot C, Pierre S, et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 2001;103:2078–2083.
18. Hultgren HN. High-altitude pulmonary edema: current concepts. Am Rev Respir Dis 1996;154:267–284.
19. Dickstein K, Cohen-Solal A, Filippatos G, et al. European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008;29:2388–2422.
20. Preston IR. Clinical perspective of hypoxia-mediated pulmonary hypertension. Antioxid Redox Signal 2007;9:711–721.